Treatment of a Candida glabrata urinary tract infection depends on whether you actually need treatment at all. The 2016 Infectious Diseases Society of America (IDSA) guidelines, which remain the most widely referenced framework, state that antifungal therapy is not recommended for asymptomatic candiduria unless the patient falls into a high-risk category. When treatment is warranted, the standard go-to for most Candida UTIs, fluconazole, often fails against C. glabrata because of the organism’s frequent resistance to azole antifungals. That leaves clinicians with a narrower and more complicated toolkit than most patients expect.
When Treatment Is and Is Not Recommended
Finding Candida in a urine culture does not automatically mean you have an infection that needs medication. A large proportion of candiduria is asymptomatic, especially in hospitalized patients with indwelling urinary catheters. The IDSA guideline is explicit: the first step is to remove or replace predisposing factors, particularly bladder catheters, rather than reaching for an antifungal.1Clinical Infectious Diseases. Executive Summary: IDSA 2016 Clinical Practice Guideline Update for the Management of Candidiasis A multi-institutional study found that asymptomatic candiduria is frequently overtreated in hospitals, with antifungals prescribed despite guidelines recommending against it.2PubMed Central. Overtreatment of Asymptomatic Candiduria among Hospitalized Patients: a Multi-institutional Study
The groups considered high risk enough to justify treatment are fairly specific: patients with severely weakened immune defenses (such as those with very low white blood cell counts), very low-birth-weight infants, and patients about to undergo a urological procedure where disrupting the urinary tract could seed the yeast into the bloodstream. If you fall outside those categories and have no symptoms, the evidence-based recommendation is to address underlying risk factors and monitor rather than treat.
Risk Factors That Predispose You to C. glabrata Candiduria
Understanding who gets these infections helps explain why treatment decisions are so context-dependent. The major risk factors include diabetes, advanced age, the presence of a urinary catheter or other urinary tract device, concurrent bacterial infection, kidney transplant, structural abnormalities of the urinary tract, ICU hospitalization, and prior antibiotic exposure.3PubMed Central. Asymptomatic Candida glabrata urinary tract infection in an immunocompetent young female: A case report Among community-acquired cases, candiduria tends to appear more often in younger patients, pregnant individuals, and people who are bedridden.
There is also the question of which patients are more likely to harbor resistant strains. A study in a Chinese tertiary hospital ICU found that an ICU stay longer than 14 days, high illness severity scores, prior antifungal exposure, and underlying lung disease were all significantly associated with antifungal-resistant C. glabrata infection.4PubMed Central. Antifungal susceptibility, molecular epidemiology, and clinical risk factors of Candida glabrata in intensive care unit in a Chinese Tertiary Hospital In practical terms, if you have been in the ICU for weeks and have already received antifungal drugs, a newly isolated C. glabrata strain is more likely to be difficult to treat.
The Fluconazole Problem
Fluconazole is the default antifungal for most Candida UTIs. It concentrates well in urine, is available as an oral tablet, and works effectively against C. albicans and several other species. For C. glabrata, however, fluconazole is often unreliable. Many C. glabrata isolates show reduced susceptibility to fluconazole or are outright resistant to it, making species identification before choosing therapy essential.
The reason C. glabrata resists azole drugs so effectively comes down to molecular pumps. The organism ramps up production of proteins called multidrug transporters, encoded by genes known as CDR1 and PDH1, that actively push azole molecules out of the yeast cell before they can do damage. In one study, ten out of twelve azole-resistant clinical isolates showed a six- to fifteen-fold increase in CDR1 expression compared to susceptible strains, while the gene encoding the azole drug target itself was barely changed.5PubMed Central. Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor The master switch behind this pump overproduction is a gene called PDR1. Activating mutations in PDR1 drive the coordinated upregulation of these transporter genes and represent the most frequent mechanism of azole resistance in C. glabrata.6PubMed. Azole Resistance in Candida glabrata
Disrupting the PDR1 gene in laboratory experiments rendered both naturally less-susceptible strains and resistant mutants highly sensitive to fluconazole, confirming that this single regulatory gene plays a role in both acquired and built-in azole resistance.7PubMed. Pdr1 regulates multidrug resistance in Candida glabrata: gene disruption and genome-wide expression studies What this means for patients is that even a C. glabrata isolate initially reported as susceptible to fluconazole can develop resistance relatively quickly, especially under drug pressure. Clinicians often treat C. glabrata UTIs with the assumption that fluconazole may not work and build their plan accordingly.
Treatment Options for Fluconazole-Resistant C. glabrata UTIs
When fluconazole is not an option, the IDSA guidelines recommend two main alternatives for lower urinary tract infections. The first is amphotericin B deoxycholate, given intravenously at a low dose for one to seven days. The second is oral flucytosine, taken four times daily for seven to ten days, or up to two weeks as monotherapy. These two drugs can also be used together.1Clinical Infectious Diseases. Executive Summary: IDSA 2016 Clinical Practice Guideline Update for the Management of Candidiasis
Amphotericin B deoxycholate can also be administered directly into the bladder as an irrigation, where a dilute solution is instilled daily for about five days. The IDSA considers this a weaker recommendation, and there is reason for caution. An older comparative trial found that while amphotericin B bladder irrigation initially cleared funguria in a higher percentage of elderly patients than oral fluconazole, patients who received the local irrigation actually had higher overall mortality at one month.8Clinical Infectious Diseases. Oral Fluconazole Compared with Bladder Irrigation with Amphotericin B for Treatment of Fungal Urinary Tract Infections in Elderly Patients That finding does not necessarily mean the irrigation itself caused harm, as sicker patients may have been more likely to receive local therapy, but it underscores that bladder irrigation is not a benign shortcut and should be reserved for situations where systemic therapy is genuinely impractical.
Flucytosine has good urinary penetration and genuine activity against most C. glabrata strains, but it carries its own risk: resistance can emerge remarkably fast. A report described two patients with stubborn C. glabrata cystitis who developed high-level flucytosine resistance during treatment, traced to mutations in a single gene called FUR1. Both patients failed therapy microbiologically.9PubMed Central. Acquired Flucytosine Resistance during Combination Therapy with Caspofungin and Flucytosine for Candida glabrata Cystitis Flucytosine also requires monitoring of blood counts and liver function, and its availability varies by country. These practical limitations mean it is rarely a simple first-choice drug even when the organism is initially susceptible.
Why Echinocandins Are Not Standard for Urinary Tract Infections
For bloodstream Candida infections, echinocandins like caspofungin and micafungin are often the first-line agents. They work well against C. glabrata in the bloodstream, so patients sometimes wonder why they are not used for UTIs. The answer is pharmacological: echinocandins are poorly excreted by the kidneys, so very little active drug ends up in the urine.10PubMed Central. Outcomes of caspofungin use in the treatment of Candida-related urinary tract infections, a case series A drug that never reaches the site of infection cannot be expected to clear it, regardless of how potent it is in a test tube.
There are, however, case reports of echinocandins being used when other options were exhausted. One case described a patient who developed C. glabrata pyelonephritis and bacteremia while taking an SGLT2 inhibitor, a diabetes drug known to increase glucose in urine and thereby encourage yeast growth. That patient was treated with micafungin combined with fluconazole for 17 days because the side-effect profiles of amphotericin B and flucytosine were considered unacceptable; the patient recovered without adverse events or recurrence over three months.11PubMed Central. A case of pyelonephritis and bacteremia caused by Candida glabrata in a patient on sodium glucose cotransporter 2 inhibitor, successfully treated with micafungin Cases like these are promising but anecdotal. They do not change the general guidance, which still excludes echinocandins from routine urinary tract infection treatment.
Treating Upper Urinary Tract Infections
A C. glabrata infection that reaches the kidney, whether through the bloodstream or by ascending from the lower urinary tract, is a more serious condition than simple cystitis. Renal candidiasis is generally treated as aggressively as a bloodstream infection. Fluconazole is still the preferred agent for susceptible organisms, typically at a daily oral dose for two weeks. For fluconazole-resistant isolates, flucytosine or intravenous amphotericin B deoxycholate are used, with treatment extended to about 14 days for both.12Urogenital Tract Infection. Management of Candida Urinary Tract Infection in the Elderly
One important caveat for kidney infections: lipid formulations of amphotericin B, which are generally better tolerated than the deoxycholate version, should not be used for renal candidiasis. These lipid preparations concentrate in the liver and spleen rather than the kidneys, and treatment failures have been reported when they were used for kidney infections. The older, harsher deoxycholate formulation is specifically needed because it distributes to renal tissue.
The pH Factor in C. glabrata Treatment
Urine pH is something clinicians rarely think about when prescribing antibiotics for bacterial UTIs, but it can substantially affect antifungal performance against C. glabrata. Laboratory testing showed that when pH drops to acidic levels, the minimum drug concentrations needed to inhibit C. glabrata growth increased dramatically for amphotericin B and for every azole drug tested. By contrast, caspofungin and flucytosine retained their activity regardless of pH.13PubMed Central. Effect of pH on in vitro susceptibility of Candida glabrata and Candida albicans to 11 antifungal agents and implications for clinical use
This has practical implications. Standard susceptibility testing in the laboratory is performed at a neutral pH of around 7.0, but actual human urine is often more acidic, sometimes significantly so. A C. glabrata isolate that looks susceptible to fluconazole or amphotericin B under standard lab conditions might behave as resistant in the acidic environment of the bladder. This mismatch between lab results and real-world drug performance is one of the underappreciated reasons that C. glabrata UTIs sometimes fail to respond to apparently appropriate therapy.
Echinocandin Resistance and What It Means for the Future
Even though echinocandins are not standard UTI drugs, the rising rate of echinocandin resistance in C. glabrata matters to UTI patients because it narrows the therapeutic safety net for anyone whose infection escalates to the bloodstream. Echinocandin resistance in C. glabrata is driven by mutations in the FKS1 and FKS2 genes. A study screening over a thousand clinical isolates found 51 with mutations in the critical regions of these genes, and nearly all of them were resistant to at least one echinocandin by susceptibility testing.14PubMed Central. Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance The amino acid changes caused by these mutations can reduce drug sensitivity at the enzyme level by a factor of 100 to 1,000 compared to normal strains.15PubMed Central. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint
Recent research has revealed that resistance can also develop through gene conversion events between FKS1 and FKS2, a structural rearrangement that current diagnostic methods tend to miss.16npj Antimicrobials and Resistance. Hotspot gene conversion between FKS1 and FKS2 in echinocandin resistant Candida glabrata serial isolates Rapid molecular detection methods, including a PCR-based assay that can identify the most common FKS mutations within about four hours, have been developed to help identify resistant strains before treatment decisions are made.17PubMed Central. Set of classical PCRs for detection of mutations in Candida glabrata FKS genes linked with echinocandin resistance Multidrug-resistant C. glabrata, meaning strains resistant to both azoles and echinocandins, remains uncommon but is increasing in surveillance data, and it represents one of the most worrying trends in clinical mycology.
Emerging Antifungals on the Horizon
The limited options for resistant C. glabrata have spurred interest in new drug classes. Ibrexafungerp is one of the most closely watched. It belongs to a class called triterpenoids and targets the same cell wall enzyme as echinocandins but through a different binding site. Crucially, ibrexafungerp is available as an oral pill and has demonstrated broad activity against wild-type, azole-resistant, and echinocandin-resistant C. glabrata in laboratory testing.18PubMed Central. Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata It has also shown effectiveness in acidic environments, which is relevant given the pH problem described above.
Ibrexafungerp is currently approved for vulvovaginal candidiasis and is under investigation for other indications. Whether it will eventually become a standard option for C. glabrata urinary tract infections depends on clinical trial data demonstrating urinary concentrations and efficacy in that specific setting, but the pharmacological profile is encouraging. For patients and clinicians who have been stuck choosing between toxic or resistance-prone options, the arrival of a new oral antifungal with activity against resistant C. glabrata is a meaningful development.
Boric Acid for C. glabrata Vaginal Infections
Boric acid deserves mention here because patients often encounter information about it when searching for C. glabrata treatments, though it applies to vaginal infections rather than urinary tract infections. For vulvovaginal candidiasis caused by C. glabrata, intravaginal boric acid suppositories have shown consistent success across several studies. A two- to three-week course achieved clinical and mycological cure in roughly two-thirds to three-quarters of women across study sites.19PubMed. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine In a study of diabetic women specifically, boric acid suppositories produced mycological cure in about 72% of those with C. glabrata, compared with roughly 33% for oral fluconazole.20PubMed. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis Earlier data in patients who had failed repeated courses of azole therapy showed similar results, with clinical improvement or cure in about 81% of episodes.21PubMed. Treatment of Torulopsis glabrata vaginitis: retrospective review of boric acid therapy
Boric acid is toxic if swallowed and should never be used orally or during pregnancy. Its role is limited to intravaginal application for vaginal C. glabrata infections, and it has no established use for bladder or kidney infections. Still, for women dealing with recurrent azole-resistant C. glabrata vaginitis, it is one of the better-supported alternatives in the literature, and it is inexpensive and widely available as a compounded suppository.
SGLT2 Inhibitors and a Newer Risk Factor
C. glabrata is an opportunistic organism that thrives when conditions favor yeast growth, and one of the newer risk factors that clinicians are watching is the widespread use of SGLT2 inhibitor medications for diabetes and heart failure. These drugs work by blocking glucose reabsorption in the kidneys, causing excess sugar to be excreted in the urine. That glucose-rich urinary environment can act as a growth medium for Candida species. A case report documented C. glabrata pyelonephritis in a patient taking an SGLT2 inhibitor, noting that patients on these medications may be more susceptible to urinary C. glabrata infections.11PubMed Central. A case of pyelonephritis and bacteremia caused by Candida glabrata in a patient on sodium glucose cotransporter 2 inhibitor, successfully treated with micafungin Given that SGLT2 inhibitors are increasingly prescribed not only for diabetes but also for chronic kidney disease and heart failure, the pool of patients potentially at risk is growing. If you are on one of these medications and develop recurrent urinary symptoms that do not respond to standard antibacterial treatment, candidal infection is worth considering.
C. glabrata itself is phylogenetically closer to brewer’s yeast than to C. albicans, and its pathogenic mechanisms remain less well studied despite being one of the two most common Candida species isolated from the urinary tract.22PubMed Central. Investigating Candida glabrata Urinary Tract Infections (UTIs) in Mice Using Bioluminescence Imaging It does not form the long filamentous structures that C. albicans uses to invade tissue, yet it persists tenaciously in the urinary tract and acquires resistance to antifungals at a pace that keeps outrunning available therapies. The gap between how commonly it causes problems and how well we understand those problems is one of the frustrating realities of clinical mycology, and it is part of why treatment guidelines for C. glabrata UTIs still lean so heavily on expert opinion rather than large randomized trials.